Urogenital Infections and Inflammations

T.E. Bjerklund Johansen, F. M.E. Wagenlehner, Y.-H. Cho, T. Matsumoto, J. N. Krieger, D. Shoskes, K. Naber

The role of Oxalobacter formigenes in calcium oxalate stone disease

 Roswitha Siener 1


1 University Stone Centre, Department of Urology, University of Bonn, Bonn, Germany

Abstract

Calcium oxalate is the major component of about 75% of all urinary stones. Hyperoxaluria is a primary risk factor for calcium oxalate stone formation. The bioavailability of ingested oxalate and the extent of intestinal absorption of dietary oxalate are considered to be important factors in hyperoxaluria. Oxalobacter formigenes is a Gram-negative anaerobic bacterium that colonizes the intestinal tract. It is unique in that it requires oxalate both as an energy and carbon source. The only known factor which reduces colonization with O. formigenes is the treatment with antibiotics to which the bacterium has been reported to be sensitive. A deficiency of oxalate degradation by O. formigenes may increase urinary oxalate excretion, attributed to decreased intestinal oxalate degradation, leaving more oxalate available for absorption at a constant intestinal absorption rate. A lack of colonization with O. formigenes increases the risk of recurrent calcium oxalate stone formation. While evidence is emerging that orally administered O. formigenes can reduce urinary and plasma oxalate, the possible treatment with a probiotic still remains a challenge.


Summary of recommendations

  1. Colonization with O. formigenes is associated with a reduced risk of calcium oxalate stone formation probably resulting from a decreased excretion of urinary oxalate (GoR B)
  2. Several studies have suggested that colonization with O. formigenes is markedly affected by use of antibiotics to which the bacterium is sensitive (GoR B).
  3. Long-term controlled studies on the treatment of idiopathic calcium oxalate stone formers with O. formigenes are lacking so far.

1 Introduction

Calcium oxalate is the most common stone constituent, and is suggested to be the major mineral in about 75% of all urinary stones [1]. Hyperoxaluria is a primary risk factor for calcium oxalate stone formation. Since the molar oxalate-to-calcium ratio is normally at 1:10, even slight changes in urinary oxalate concentration exert much larger effects on crystallization and stone formation than comparable changes in the calcium concentration [2].

Hyperoxaluria can result from a high dietary oxalate intake, intestinal hyperabsorption of oxalate from the diet, or an increased endogenous production of oxalate from ingested or metabolically-generated precursors. The amount of oxalate excreted in urine has a significant impact on calcium oxalate supersaturation and stone formation. It has been suggested that dietary oxalate contributes up to 50% to urinary oxalate excretion [3]. The bioavailability of ingested oxalate and the extent of absorption of dietary oxalate may be important factors in hyperoxaluria.

A high dietary oxalate intake plays a key role in idiopathic hyperoxaluria. Some foods, particularly vegetables, cereals and nuts such as sesame, almonds, wheat bran, mangold, rhubarb, sorrel and spinach, are known to contain high oxalate concentrations [4], [5], [6]. Among beverages, green and black teas as well as various vegetable juices were found to contain considerable amounts of highly bioavailable, soluble oxalate [4], [7], [8]. A high dietary intake of oxalate can significantly increase urinary oxalate excretion even in healthy individuals without disturbances in oxalate metabolism [9].

Intestinal hyperabsorption of oxalate can considerably contribute to urinary oxalate, even in the absence of gastrointestinal disorders. A study using the standardized [13C2] oxalate absorption test revealed a significantly higher mean intestinal oxalate absorption in idiopathic calcium oxalate stone formers (10.2%) compared to healthy controls (8.0%) [10]. However, the reason for this difference is unclear. Intestinal oxalate absorption greater than 10% was found in only 28% of healthy subjects, but in 46% of patients. Oxalate absorption greater than 20% only occurred in stone formers.

2 Methods

A systematic literature search was performed in PubMed over the last 40 years using the following key word: Oxalobacter/formigenes. Search results were limited to studies written in the English language. A total of 176 publications were identified, which were screened by title and, when appropriate, abstract. After exclusion of duplicates, a total of twenty-two were included in the analysis. It should be stated that there are no meta-analyses for Oxalobacter formigenes published in the literature. The studies were rated according to the level of evidence (LoE) and the grade of recommendation (GoR) using ICUD standards.

3 Results

3.1 Oxalobacter formigenes

Oxalobacter formigenes is a Gram-negative anaerobic bacterium that colonizes the intestinal tract of humans [11]. It is unique in that it requires oxalate both as an energy and carbon source. There is very little known about the biology of the organism, particularly on how it establishes and maintains gut colonization.

The only known factor which reduces colonization with Oxalobacter formigenes is the treatment with antibiotics. Several studies have suggested that colonization with O. formigenes is markedly affected by use of antibiotics [12], [13], [14], [15], [16], [17], [18]. In a study of 37 idiopathic calcium oxalate stone formers, only 11 (30%) tested positive for O. formigenes, whereas 26 (70%) tested negative [19]. Analysis of a history of use of antibiotics revealed that only 13% of O. formigenes-positive patients had taken antibiotics, whereas 81% of O. formigenes-negative patients had received antibiotic treatment before the start of the study. O. formigenes has been reported to be sensitive to a variety of antibiotics commonly used in clinical practice for the treatment of a broad range of infections [13], [15], [18]. These antibiotics include macrolides, such as erythromycin and clarithromycin, metronidazole, and doxycycline.

A prospective study in patients who where undergoing upper endoscopy and biopsy revealed that antibiotics for Helicobacter pylori infection leads to persistently reduced intestinal colonization rates with O. formigenes [15]. The absence of O. formigenes colonization in women could be attributed to frequent use of antibiotics owing to recurrent urinary tract infections, which have been found to be associated with increased oxalate excretion [20]. According to a recent study, the relatively lower rate of O. formigenes detection in relation to other populations outside the United States provides further evidence to support a general trend of the disappearance of this organism with socioeconomic development, likely due to higher general use of antibiotics within these populations [21]. A lack of colonization with O. formigenes increases the risk of recurrent calcium oxalate stone formation [16], [17], [19], [22], [23], [24], [25].

3.2 Oxalobacter formigenes and urinary oxalate excretion

The lasting elimination of O. formigenes could lead to a reduced rate or deficiency of oxalate degradation in the colon [16]. Oxalate degradation by O. formigenes might be expected to reduce the extent of urinary oxalate excretion. Whereas several studies have linked the absence of O. formigenes to higher urinary oxalate excretion [12], [23], [24], [26], others revealed no significant difference in urinary oxalate excretion between patients who tested positive or negative for O. formigenes [17], [27]. However, a major limitation is that none of these studies in stone formers were conducted under controlled conditions. A study in calcium oxalate stone formers on two days under controlled, standardized diet revealed that mean urinary oxalate excretion was significantly lower in O. formigenes-positive patients (0.318 and 0.367 mmol/24h, respectively) than in those who were O. formigenes-negative (0.454 and 0.474 mmol/24h, respectively) (p=0.003 and p=0.043, respectively) [19].

3.3 Oxalobacter formigenes and intestinal oxalate absorption

The understanding of the role of O. formigenes in oxalate metabolism is still limited. It has been hypothesized that the absence of this bacterium could be associated with higher intestinal oxalate absorption [16], [28], [29]. In our study in 37 idiopathic calcium oxalate stone formers, no difference in mean oxalate absorption, measured by [13C2]oxalate absorption test, was observed between O. formigenes colonized and noncolonized patients [19]. Intestinal oxalate absorption was 11.5±4.6% in O. formigenes-positive patients and 11.3±5.9% in O. formigenes-negative patients, which is consistent with mean intestinal absorption of 10.2±5.2% in 120 recurrent idiopathic calcium oxalate stone formers [10], [19]. Similarly, Knight et al. (2011) reported in 38 calcium oxalate stone formers that absorption was not significantly different in colonized and noncolonized subjects [27]. Overall, these findings suggest that intestinal oxalate absorption is not modulated by O. formigenes.

3.4 Oxalobacter formigenes and enteric oxalate secretion

There is still a significant lack of knowledge on the mechanism of action of O. formigenes colonization in patients with idiopathic calcium oxalate stone disease. The only study investigating the effect of colonization with O. formigenes on plasma oxalate concentration in idiopathic stone patients revealed that mean plasma oxalate concentration was more than threefold higher in patients without O. formigenes (5.79 µmol/l) than in colonized stone formers (1.70 µmol/l) [19]. While glomerular filtration rate was similar in both groups, the results of the study suggest that differences in urinary oxalate excretion were not apparently associated with either changes in glomerular filtration or tubular secretion of oxalate.

A hypothetical explanation for the higher plasma oxalate concentration in noncolonized stone formers is that the absence of O. formigenes is attributable to altered intestinal oxalate transport. Rat models have suggested that Oxalobacter, in addition to degrading dietary sources of oxalate, interacts physiologically with colonic mucosa by inducing active secretion of endogenously produced oxalate [30]. Hatch et al. (2006) demonstrated that this bacterial-enterocyte interaction results in a significant reduction in urinary oxalate excretion owing to this enteric oxalate shunt [30]. The latter study was also the first to demonstrate that endogenously derived oxalate can sustain O. formigenes colonization. In patients with primary hyperoxaluria, oral administration of O. formigenes has been shown to significantly induce enteric oxalate secretion, possibly by contributing to a transepithelial gradient favoring intestinal secretion of endogenous oxalate [31], [32].

3.5 Treatment with Oxalobacter formigenes

Results of clinical trials on the use of O. formigenes as a probiotic to reduce urinary oxalate excretion are inconsistent. Despite favorable results in a pilot study [31], the efficacy of orally administered O. formigenes for reducing urinary oxalate excretion could not be confirmed in a multicenter trial in 42 patients with primary hyperoxaluria [33]. In contrast, a recent study in 80 calcium oxalate stone formers randomized to receive either KMgCit or O. formigenes preparation revealed that the incidence of hyperoxaluria decreased at 1 month compared to baseline in both groups, while other urinary metabolic abnormalities remained similar [34]. However, the possible use of O. formigenes as a probiotic therapy remains a challenge with several hurdles to overcome before reaching clinical practice [35]. The main limitation of the use of O. formigenes is that its effect remains as long as the preparation is taken, indicating only transient gut colonization [31], [35].

4 Further research

Further studies with larger sample sizes are needed to define the exact role of O. formigenes colonization in calcium oxalate stone disease and to evaluate the efficacy of O. formigenes during long-term treatment.

5 Conclusions

Colonization with O. formigenes is associated with a reduced risk of calcium oxalate stone formation. Recent findings revealed that colonization with O. formigenes may reduce urinary oxalate excretion, attributed to increased intestinal oxalate degradation, leaving less oxalate available for absorption at a constant intestinal absorption rate. The observation that active enteric secretion of endogenously produced oxalate may be induced or enhanced by O. formigenes, thereby decreasing plasma oxalate concentration, may have important consequences for future hyperoxalemia treatment strategies. However, colonization with O. formigenes may be markedly affected by use of antibiotics to which the bacterium is sensitive. While evidence is emerging that orally administered O. formigenes can reduce urinary and plasma oxalate, the possible treatment with a probiotic still remains a challenge. Because only transient gut colonization with O. formigenes has been achieved so far, attention should be focused also on additional oxalate-degrading microorganisms such as Lactobacillus and Bifidobacterium strains and oxalate-degrading enzymes.


References

[1] Hesse A, Siener R. Current aspects of epidemiology and nutrition in urinary stone disease. World J Urol. 1997;15(3):165-71. DOI: 10.1007/BF02201853
[2] Siener R, Schade N, Nicolay C, von Unruh GE, Hesse A. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients. J Urol. 2005 May;173(5):1601-5. DOI: 10.1097/01.ju.0000154626.16349.d3
[3] Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001 Jan;59(1):270-6. DOI: 10.1046/j.1523-1755.2001.00488.x
[4] Hönow R, Hesse A. Comparison of extraction methods for the determination of soluble and total oxalate in foods by HPLC-enzyme-reactor. Food Chem. 2002;78(4):511-21. DOI: 10.1016/S0308-8146(02)00212-1
[5] Siener R, Hönow R, Seidler A, Voss S, Hesse A. Oxalate contents of species of the Polygonaceae, Amaranthaceae and Chenopodiaceae families. Food Chem. 2006;98: 220-4. DOI: 10.1016/j.foodchem.2005.05.059
[6] Siener R, Hönow R, Voss S, Seidler A, Hesse A. Oxalate content of cereals and cereal products. J Agric Food Chem. 2006 Apr;54(8):3008-11. DOI: 10.1021/jf052776v
[7] Hönow R, Gu KL, Hesse A, Siener R. Oxalate content of green tea of different origin, quality, preparation and time of harvest. Urol Res. 2010 Oct;38(5):377-81. DOI: 10.1007/s00240-009-0245-x
[8] Siener R, Seidler A, Voss S, Hesse A. The oxalate content of fruit and vegetable juices, nectars and drinks. J Food Compos Anal. 2016;45:108-12. DOI: 10.1016/j.jfca.2015.10.004
[9] Siener R, Bade DJ, Hesse A, Hoppe B. Dietary hyperoxaluria is not reduced by treatment with lactic acid bacteria. J Transl Med. 2013;11:306. DOI: 10.1186/1479-5876-11-306
[10] Voss S, Hesse A, Zimmermann DJ, Sauerbruch T, von Unruh GE. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [13C2]oxalate absorption test. J Urol. 2006;175:1711-5. DOI: 10.1016/S0022-5347(05)01001-3
[11] Allison MJ, Dawson KA, Mayberry WR, Foss JG. Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol. 1985 Feb;141(1):1-7. DOI: 10.1007/BF00446731
[12] Sidhu H, Hoppe B, Hesse A, Tenbrock K, Brömme S, Rietschel E, Peck AB. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet. 1998 Sep 26;352(9133):1026-9.DOI: 10.1016/S0140-6736(98)03038-4
[13] Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS. Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol. 2002 Aug;68(8):3841-7. DOI: 10.1128/AEM.68.8.3841-3847.2002
[14] Kelly JP, Curhan GC, Cave DR, Anderson TE, Kaufman DW. Factors related to colonization with Oxalobacter formigenes in U.S. adults. J Endourol. 2011 Apr;25(4):673-9. DOI: 10.1089/end.2010.0462
[15] Kharlamb V, Schelker J, Francois F, Jiang J, Holmes RP, Goldfarb DS. Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes. J Endourol. 2011 Nov;25(11):1781-5. DOI: 10.1089/end.2011.0243
[16] Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol. 1999 Nov;10 Suppl 14:S334-40.
[17] Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, Cave DR. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol. 2008 Jun;19(6):1197-203. DOI: 10.1681/ASN.2007101058
[18] Lange JN, Wood KD, Wong H, Otto R, Mufarrij PW, Knight J, Akpinar H, Holmes RP, Assimos DG. Sensitivity of human strains of Oxalobacter formigenes to commonly prescribed antibiotics. Urology. 2012 Jun;79(6):1286-9. DOI: 10.1016/j.urology.2011.11.017
[19] Siener R, Bangen U, Sidhu H, Hönow R, von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013 Jun;83(6):1144-9. DOI: 10.1038/ki.2013.104
[20] Siener R, Ebert D, Hesse A. Urinary oxalate excretion in female calcium oxalate stone formers with and without a history of recurrent urinary tract infections. Urol Res. 2001 Aug;29(4):245-8. DOI: 10.1007/s002400100198
[21] Barnett C, Nazzal L, Goldfarb DS, Blaser MJ. The presence of Oxalobacter formigenes in the microbiome of healthy young adults. J Urol. 2016 Feb;195(2):499-506. DOI: 10.1016/j.juro.2015.08.070
[22] Kumar R, Mukherjee M, Bhandari M, Kumar A, Sidhu H, Mittal RD. Role of Oxalobacter formigenes in calcium oxalate stone disease: a study from North India. Eur Urol. 2002 Mar;41(3):318-22. DOI: 10.1016/S0302-2838(02)00040-4
[23] Troxel SA, Sidhu H, Kaul P, Low RK. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate. J Endourol. 2003 Apr;17(3):173-6. DOI: 10.1089/089277903321618743
[24] Kwak C, Kim HK, Kim EC, Choi MS, Kim HH. Urinary oxalate levels and the enteric bacterium Oxalobacter formigenes in patients with calcium oxalate urolithiasis. Eur Urol. 2003 Oct;44(4):475-81. DOI: 10.1016/S0302-2838(03)00318-X
[25] Mittal RD, Kumar R, Mittal B, Prasad R, Bhandari M. Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract. 2003 Oct-Dec;12(4):208-13. DOI: 10.1159/000072285
[26] Mikami K, Akakura K, Takei K, Ueda T, Mizoguchi K, Noda M, Miyake M, Ito H. Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation. Int J Urol. 2003 Jun;10(6):293-6. DOI: 10.1046/j.1442-2042.2003.00634.x
[27] Knight J, Jiang J, Wood KD, Holmes RP, Assimos DG. Oxalate and sucralose absorption in idiopathic calcium oxalate stone formers. Urology. 2011 Aug;78(2):475.e9-475.e13. DOI: 10.1016/j.urology.2011.04.008
[28] Liebman M, Al-Wahsh IA. Probiotics and other key determinants of dietary oxalate absorption. Adv Nutr. 2011 May;2(3):254-60. DOI: 10.3945/an.111.000414
[29] Argenzio RA, Liacos JA, Allison MJ. Intestinal oxalate-degrading bacteria reduce oxalate absorption and toxicity in guinea pigs. J Nutr. 1988 Jun;118(6):787-92.
[30] Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int. 2006 Feb;69(4):691-8. DOI: 10.1038/sj.ki.5000162
[31] Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006 Oct;70(7):1305-11. DOI: 10.1038/sj.ki.5001707
[32] Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB. Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis. 2011 Sep;58(3):453-5. DOI: 10.1053/j.ajkd.2011.05.012
[33] Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant. 2011 Nov;26(11):3609-15. DOI: 10.1093/ndt/gfr107
[34] Jairath A, Parekh N, Otano N, Mishra S, Ganpule A, Sabnis R, Desai M. Oxalobacter formigenes: Opening the door to probiotic therapy for the treatment of hyperoxaluria. Scand J Urol. 2015;49(4):334-7. DOI: 10.3109/21681805.2014.996251
[35] Peck AB, Canales BK, Nguyen CQ. Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease? Urolithiasis. 2016 Feb;44(1):45-50. DOI: 10.1007/s00240-015-0845-6

The ZB MED – Information Center for Life Sciences, Germany, together with the European Association of Urology (EAU) provided the opportunity to publish a “Living Textbook” on “Urogenital Infections and Inflammations” in an open access form. This “Living Textbook” represents also an update of the Textbook on Urogenital Infections published 2010 by the International Consultation on Urological Infections and the EAU: http://www.icud.info/urogenitalinfections.html.

The “Living Textbook” will cover infections and inflammations of the kidney, the urinary tract, as well as the male and female genital tract considering pathogenesis, diagnostics, treatment, prophylaxis and future aspects. The “Living Textbook” will be structured into about 26 Sections each with two section co-chairs responsible for peer review of the chapters of each section. Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

The editors hope that this “Living Textbook” may become a useful instrument for physicians of different specialties taking care about patients suffering from these diseases.

Truls E. Bjerklund Johansen (Norway),

Florian ME Wagenlehner (Germany),

Yong-Hyun Cho (South Korea),

Tetsuro Matsumoto (Japan),

John N Krieger (USA),

Daniel Shoskes (USA),

Kurt G. Naber (Germany).

Publishing at PUBLISSO

Your chapter will be published at the PUBLISSO platform (https://books.publisso.de).

Information for corresponding authors

It is necessary for all corresponding authors to register at PUBLISSO.
To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

After registration, please complete your user profile. Information from your user profile will appear in the published chapter and the authors board of the book (http://books.publisso.de/publisso_gold/book/52). If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.
(If you do not want to be displayed in the authors board, but stay registered, you can disable this feature in your profile settings. In this case, your affiliation (publication data) will be displayed in the published chapter only.)

We kindly ask you to provide the co-authors email addresses in the manuscript so that we can contact them in case of queries.

Information for co-authors

After publication of your chapter, your affiliation (publication data) will be displayed in the published chapter.

If you also want to be displayed in the authors board of the book (http://books.publisso.de/publisso_gold/book/52), we kindly ask you to register at PUBLISSO. If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.

To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

If you do not want to be displayed in the authors board of the book, you do not have to register. Your affiliation (publication data) will be displayed in the published chapter only.

Support

If you have any further questions please don’t hesitate to contact the PUBLISSO editorial office:

E-Mail: livingbooks@zbmed.de
Phone: +49 221 478-7093

General

The textbook will be structured in sections with two co-chairs each. Each section will start with an introductory chapter written by the two respective co-chairs presented like an editorial commentary in regard to the following chapters (see proposed contents of the book). The two co-chairs of each section will also peer review all chapters in their section and stimulate a consensus discussion within their section together with the authors and the main editors if needed.

Chapters

Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

Manuscript

Each manuscript should have up to approximately 3,000 words (excluding abstract, tables/figures and references). The abstract should count about 300 words.

Structure

The outline of each chapter should be structured as follows (similar as in the edition 2010, which can be downloaded for free: http://www.icud.info/urogenitalinfections.html):

  1. Abstract
  2. Summary of recommendations*/key notes*
    (*which ever term is more appropriate)
  3. Introduction
  4. Methods
  5. Results
  6. Further research
  7. Conclusions
  8. Acknowledgement
  9. Conflict of interest of each author
  10. References

Citation style

As a citation style, the Vancouver style is preferred.

Please mark your references in the text with square brackets ([1], [2], ...).

Summary of recommendations

We would like to have the Summary of recommendations at the beginning after the abstract (as in the edition 2010). However, we do not expect as in the edition 2010, that each recommendation is also specified according to Level of Evidence and Grade of Recommendation, because such a claim would not only need a systematic literature search (see below), but also a structured discussion in a defined group of experts.

Systematic literature search

A systematic literature search should be performed, at least of PUBMED/MEDLINE but ideally of several relevant databases in addition (like Cochrane CENTRAL) to find recent, high quality systematic reviews and/or primary research studies. It is not expected to perform for all chapters a de novo systematic review, if such reviews are already published recently, but it still may be indicated for some items. For questions relating therapy, it should be focused on evidence from (systematic reviews of) randomized controlled trials if available.

The method of the systematic literature search needs to be fully described in the section “Methods”, e.g.:

“A systematic literature search was performed for the last ... (usually 10) years in MEDLINE, Cochrane etc. with the following key words ... and the following limitations: e.g. UTI, age (adult?), ... clinical studies ... English ... abstract available ... only peer reviewed ...

A total of ... publications were identified, which were screened by title and abstract ... After exclusion of duplicates ... a total of ... were included into the review (analysis), supplemented by citations or known to the authors ... ”.

Clinical topics

Clinical topics should be focused on the importance to clinical practice according to the up to date scientific knowledge as presented in the literature. It should relate to questions/complaints/symptoms of patient/population concerning definition, diagnosis, therapy/prevention, intervention, and outcome in comparison, if different approaches are feasible. Please choose patient-important outcomes and focus on those, which you deem critical for decision-making.

Level of evidence and grade of recommendations

Any recommendation should be based on the level of evidence and the grade of recommendation. For this purpose the following system, modified from the Oxford Centre for Evidence-based Medicine should be used (EAU guidelines 2015):

Level of evidence (LE)

Level Type of evidence
1a Evidence obtained from meta-analysis of randomised trials
1b Evidence obtained from at least one randomised trial
2a Evidence obtained from one well-designed controlled study without randomization
2b Evidence obtained from at least one other type of well-designed quasi-experimental study
3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports.
4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities.

Grade of Recommendations (GoR)

Grade Nature of recommendations
A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial
B Based on well-conducted clinical studies, but without randomised clinical trials
C Made despite the absence of directly applicable clinical studies of good quality

Comments (EAU guidelines 2015)

The aim of assigning a LE and grading recommendations is to provide transparency between the underlying evidence and the recommendation given.

It should be noted that when recommendations are graded, the link between the level of evidence and grade of recommendation is not directly linear. Availability of randomized controlled trials may not necessarily translate into a grade “A” recommendation where there are methodological limitations or disparity in published results.

Alternatively, absence of high level evidence does not necessarily preclude a grade A recommendation, if there is overwhelming clinical experience and consensus. In addition, there may be exceptional situations where corroborating studies cannot be performed, perhaps for ethical or other reasons and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor – has to be balanced against benefits and burdens, values and preferences and costs when a grade is assigned.

Since the same rating system should be used in all chapters, for the sake of brevity the same sentence could be used in “Methods” for all manuscripts, because the rating system will be described in details in the Preface of the book:

“The studies were rated according to the level of evidence and the strength of recommendations graded according to a system used in the EAU guidelines modified from the Oxford Centre for Evidence-based Medicine [1].”

References

[1] European Association of Urology. Guidelines. Methodology section. 2015 ed. Arnhem: European Association of Urology; 2015. p. 3. ISBN/EAN: 978-90-79754-80-9. Available from: http://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn..pdf

The Living Handbook of Urogenital Infections and Inflammations is issued by:

European Association of Urology
att. Maurice Schlief, EAU executive manager business affairs

P.O.Box 30016
NL-6803 AA Arnhem, The Netherlands

Phone: 0031-26-38.90.680
E-mail: m.schlief@uroweb.org

Editor in Chief

responsible for the contents according to § 5 TMG and § 55 Abs. 2 RStV (Germany):

Kurt G. Naber, MD, PhD
Assoc. Professor of Urology

Technical University of Munich
Karl-Bickleder-Str. 44c
94315 Straubing, Germany

E-mail: kurt.naber@nabers.de

John N. Krieger MD, PhD

University of Washington Section of Urology

more

Daniel Shoskes MD, PhD

Cleveland Clinic Glickman Urological and Kidney Institute

more

Yong-Hyun Cho MD, PhD

St. Mary's Hospital, The Catholic University of Korea Department of Urology

more

Tetsuro Matsumoto MD, PhD

University of Occupational and Environmental Health Department of Urology

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen Clinic of Urology and Andrology

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital Urology Department

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Punit Bansal MD, PhD

R G Stone and Super Specialty Hospital
Department of Urology

more

Riccardo Bartoletti

University of Pisa
Department of Translational Research and New Technologies

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital
Urology Department

more

PD Dr. med. Gernot Bonkat

University Basel
alta uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB)

more

Prof. Tommaso Cai MD

Santa Chiara Regional Hospital
Dept. of Urology

more

Dr Leyland Chuang

Ng Teng Fong Hospital, National University Health System
Department of Medicine

more

Prof. Milan Cizman

University Medical Centre
Department of Infectious Diseases

more

Alison Crawford MSc

Queen's University
Department of Psychology

more

Pfofessor Svetlana Dubrovina MD, PhD

Rostov Medical State University
Obstetrics and Gynaecology

more

Dr Valerie Huei Li Gan MBBS (S'pore), MRCS (Edin), MMed (Surg), FAMS (Urology)

Singapore General Hospital
Department of Urology

more

Philip Hanno

University of Pennsylvania

more

Ass prof MD Gundela Holmdahl

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Udo B. Hoyme

HELIOS Hospital Erfurt Ltd.
Department of Gynecology and Obstetrics

more

David Hunstad

Washington University School of Medicine
Pediatrics / Molecular Microbiology

more

Gitte M. Hvistendahl

Aarhus University Hospital

more

Prof. Michael KOGAN M.D., PhD

Rostov State Medical University
Department of Urology

more

Dr Akihiro Kanematsu

Hyogo College of Medicine
Department of Urology

more

Frieder Keller

University Hospital Ulm
Department Internal Medicine 1, Nephrology

more

Professor Katarzyna Kilis-Pstrusinska PhD, MD

Wroclaw Medical University
Department of Pediatric Nephrology

more

MD, PhD Tae-Hyoung Kim

Chung-Ang University
Urology

more

John N. Krieger MD, PhD

University of Washington
Section of Urology

more

Prof Ekaterina Kulchavenya

Novosibirsk Research TB Institute, Novosibirsk State Medical University

more

Dr Christina Kåbjörn Gustafsson

Ryhov Hospital Jönköping
Pathology

more

Dr. Bela Köves

South Pest Teaching Hospital
Department of Urology

more

Iara Linhares

Dr. med. Giuseppe Magistro

Ludwig-Maximilians-University of Munich
Department of Urology

more

Vittorio Magri

ASST-North
Urologic Clinic

more

András Magyar

South-Pest Hospital
Department of Urology

more

Professor Emeritus Brian Morris

University of Sydney
School of Medical Sciences

more

Baerbel Muendner-Hensen

ICA-Deutschland e.V.

more

Stephen F. Murphy

Feinberg School of Medicine, Northwestern University
Department of Urology

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Prof. Yulia Naboka

Rostov State Medical University
Department of Microbiology

more

Dr. J. Curtis Nickel MD

Queen's University
Department of Urology

more

Professor Ralph Peeker MD PhD

University of Gothenburg
Department of Urology

more

Tamara Perepanova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology

more

Prof. Gianpaolo Perletti M. Clin. Pharmacol.

University of Insubria
Department of Biotechnology and Life Sciences

more

Felice Petraglia

Department of Biomedical, Experimental and Clinical Sciences, University of Florence
Obstetrics and Gynecology

more

Michel Pontari

Temple University School of Medicine
Department of Urology

more

Dr. Jörgen Quaghebeur PhD. Med. Sci.

University Hospital Antwerp and University Antwerp
Department of Urology

more

Yazan F. Rawashdeh

Aarhus University Hospital
Paediatric Urology Section, Department of Urology

more

Professor Claus Riedl MD

-
Urology

more

Matthew Roberts

The University of Queensland
Faculty of Medicine

more

PD Dr. med Guido Schmiemann MPH

Institut für Public Health und Pflegeforschung, Universität Bremen
Abteilung Versorgungsforschung

more

Caroline Schneeberger MD PhD

Academic Medical Center (AMC)

more

Prof. Dr. med. Peter Schneede

Klinikum Memmingen
Department of Urology

more

Aaron C. Shoskes

Des Moines University Medical College of Ostheopathic Medicine

more

Daniel Shoskes MD, PhD

Cleveland Clinic
Glickman Urological and Kidney Institute

more

Prof. Dr. Roswitha Siener

University of Bonn
University Stone Centre, Department of Urology

more

Sofia Sjöström

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Mathew Sorensen

University of Washington School of Medicine
Department of Urology

more

Prof. Dr. Dr. Walter Ludwig Strohmaier FEBU

Regiomed-Klinikum Coburg. Medical School Regiomed
Urology and Paediatric Urology

more

Satoshi Takahashi

Sapporo Medical University School of Medicine
Department of Infection Control and Laboratory Medicine

more

Professor Paul Anantharajah Tambyah

Yong Loo Lin School of Medicine, National University Hospital
Department of Medicine

more

Peter Tenke

Jahn Ferenc South Pest Teaching Hospital
Department of Urology

more

Praveen Thumbikat


Department of Urology

more

Dr. Jose Tiran Saucedo

IMIGO / Universidad de Monterrey
Obstetrics and Gynaecology

more

Dominic Tran-Nguyen

Des Moines University

more

Dean Tripp

Queen's University
Psychology, Anesthesia & Urology

more

Prof. SEONGHEON WIE

The Catholic University of Korea, St. Vincent's Hospital
Division of Infectious Diseases, Department of Internal Medicine

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen
Clinic of Urology and Andrology

more

Assoc. Prof. Christian Wejse

Aarhus University, Aarhus University Hospital
Department of Infectious Diseases/Center for Global Health, Dept of Public Health

more

Prof. Dr. Mete Çek

Trakya University, School of Medicine
Urology

more